Literature DB >> 1312853

The effect of saturation of ACE binding sites on the pharmacokinetics of enalaprilat in man.

J R Wade1, P A Meredith, D M Hughes, H L Elliott.   

Abstract

1. Eight healthy male volunteers received oral enalapril, 10 mg, in the presence and absence of pretreatment with captopril, 50 mg, twice daily for 5 days. 2. Enalaprilat pharmacokinetics were characterised after both doses of enalapril to investigate the effect of saturating ACE binding sites by pretreatment with captopril. 3. The pharmacokinetics of enalaprilat were best described by a one compartment model with zero order input incorporating saturable binding to plasma and tissue ACE. 4. Values of AUC (0.72 h) for enalaprilat were 419 +/- 97 and 450 +/- 87 ng ml-1 h in the presence and absence of captopril, respectively. The difference was not statistically significant nor were there any other differences in model parameters. 5. Induction of ACE by captopril resulting in an increase in the number of ACE binding sites, may have obscured any effect of captopril on the occupancy of ACE binding sites by enalapril.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1312853      PMCID: PMC1381301          DOI: 10.1111/j.1365-2125.1992.tb04018.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  21 in total

1.  [Glycine-1-14C]hippuryl-L-histidyl-L-leucine: a substrate for the radiochemical assay of angiotensin converting enzyme.

Authors:  M S Rohrbach
Journal:  Anal Biochem       Date:  1978-01       Impact factor: 3.365

Review 2.  Vascular angiotensin pathways: a new therapeutic target.

Authors:  V J Dzau
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

3.  Opposite effects of captopril on angiotensin I-converting enzyme 'activity' and 'concentration'; relation between enzyme inhibition and long-term blood pressure response.

Authors:  F Boomsma; J H de Bruyn; F H Derkx; M A Schalekamp
Journal:  Clin Sci (Lond)       Date:  1981-05       Impact factor: 6.124

4.  Disposition of captopril in normal subjects.

Authors:  K J Kripalani; D N McKinstry; S M Singhvi; D A Willard; R A Vukovich; B H Migdalof
Journal:  Clin Pharmacol Ther       Date:  1980-05       Impact factor: 6.875

5.  Automated kinetic assay of angiotensin-converting enzyme in serum.

Authors:  B Beneteau; B Baudin; G Morgant; J Giboudeau; F C Baumann
Journal:  Clin Chem       Date:  1986-05       Impact factor: 8.327

6.  Determination of captopril and its mixed disulphides in plasma and urine by high-performance liquid chromatography.

Authors:  K Hayashi; M Miyamoto; Y Sekine
Journal:  J Chromatogr       Date:  1985-02-27

7.  Induction of angiotensin I-converting enzyme rat lung with Captopril (SQ 14225).

Authors:  F Fyhrquist; T Forslund; I Tikkanen; C Grönhagen-Riska
Journal:  Eur J Pharmacol       Date:  1980-10-31       Impact factor: 4.432

8.  Once-daily treatment of essential hypertension with captopril.

Authors:  J A Schoenberger; D J Wilson
Journal:  J Clin Hypertens       Date:  1986-12       Impact factor: 3.738

9.  High-performance liquid chromatographic analysis of captopril in plasma.

Authors:  B Jarrott; A Anderson; R Hooper; W J Louis
Journal:  J Pharm Sci       Date:  1981-06       Impact factor: 3.534

10.  Captopril kinetics.

Authors:  K L Duchin; S M Singhvi; D A Willard; B H Migdalof; D N McKinstry
Journal:  Clin Pharmacol Ther       Date:  1982-04       Impact factor: 6.875

View more
  1 in total

1.  Pharmacokinetics and pharmacodynamics of lisinopril in advanced renal failure. Consequence of dose adjustment.

Authors:  M Neubeck; D Fliser; M Pritsch; K Weisser; M Fliser; J Nussberger; E Ritz; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.